CNTX
CNTX clinical trials: Context Therapeutics Inc.
Every trial on ClinicalTrials.gov where Context Therapeutics Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 5
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CNTX on the catalyst calendar · CNTX registry changes
- Primary completion Jan 2030Sponsor estimatePhase 1NCT07545122A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple...Context Therapeutics Inc. · Triple Negative Breast Cancer (TNBC)RecruitingCNTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2028Sponsor estimatePhase 1NCT06515613A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid TumorsContext Therapeutics Inc. · Platinum-resistant Ovarian CancerRecruitingCNTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 9, 2026ActualPhase 1NCT06756035CT-95 in Advanced Cancers Associated With Mesothelin ExpressionContext Therapeutics Inc. · Mesothelin-Expressing TumorsTerminatedCNTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 23, 2023ActualPhase 1/Phase 2NCT05618613Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast CancerContext Therapeutics Inc. · Breast CancerTerminatedCNTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2023Sponsor estimatePhase 1/Phase 2NCT06938711A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast CancerContext Therapeutics Inc. · Breast CancerWithdrawnCNTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2025ActualPhase 2NCT04719273Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial CancerThomas Jefferson University · Refractory Endometrial AdenocarcinomaCompletedCNTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 3, 2024ActualPhase 2NCT03909152A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to ProgesteroneMemorial Sloan Kettering Cancer Center · Granulosa Cell Ovarian CancerCompletedCNTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 3, 2023ActualPhase 2NCT04738292Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)University of Wisconsin, Madison · ER-positive Breast CancerTerminatedCNTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 25, 2023ActualPhase 1NCT04872608A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast CancerMemorial Sloan Kettering Cancer Center · Metastatic Breast CancerWithdrawnCNTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner